Clicky

Tuesday, November 17, 2026

Earnings

Results and financial condition

FISERV INC Reports Third-Quarter Financial Results

FISERV INC releases Q3 financial results, highlighting growth and market strategies in the business services sector.

MoonLake Immunotherapeutics Reports Q3 Results for 2026

MoonLake Immunotherapeutics files its Q3 2026 results, showcasing financial performance and operational updates in the pharmaceutical sector.

LifeCore Biomedical reports strong Q3 results, revenue growth

LifeCore Biomedical, Inc. announces strong Q3 results with significant revenue growth, reflecting its success in the pharmaceutical preparations sector.

uniQure reports Q3 results, advances Huntington's disease therapy

uniQure N.V. announces Q3 2026 financial results, highlighting FDA priority review for AMT-130 in Huntington's disease and strong cash reserves.

Shoals Technologies reports strong Q3 results, raises outlook

Shoals Technologies Group, Inc. announces strong Q3 2026 financial results with revenue growth, increased profitability, and a positive outlook for 2027.

Viridian Therapeutics reports Q3 2026 financial results

Viridian Therapeutics announces strong Q3 2026 results, highlighting Lumvoa's success and upcoming drug submissions, signaling growth in the pharmaceutical sector.

Datadog Reports 35% Revenue Growth in Q3 2026 Results

Datadog, Inc. announces a 35% revenue growth in Q3 2026, reaching $1.20 billion, highlighting strong demand for its AI-powered observability platform.

Geron Corp reports Q3 2026 results, expands RYTELO access

Geron Corp announces strong Q3 2026 results with a 5% revenue increase for RYTELO and plans for European market expansion.

Lifecore Biomedical reports third-quarter financial results

Lifecore Biomedical announces third-quarter results with declining revenue and increased losses, while securing new projects for future growth.

SelectQuote Reports Q1 Results with $20.3M Net Loss

SelectQuote, Inc. announces its Q1 fiscal 2027 results, revealing $280M in revenue and a net loss of $20.3M as it navigates industry challenges.

Rapport Therapeutics announces Q3 2026 financial results

Rapport Therapeutics, Inc. shares Q3 2026 financial results and business highlights, signaling ongoing developments in the pharmaceutical sector.

SharkNinja reports strong Q3 results, reflects growth strategy

SharkNinja, Inc. reports third-quarter results, highlighting growth in the household appliances sector and strategic initiatives for continued success.

CPI Card Group Reports Strong Q3 Results Amid Growth

CPI Card Group Inc. announces strong third-quarter results, reflecting growth in revenue and net income, impacting the commercial printing industry.

RYTHM, Inc. releases Q3 2026 financial results

RYTHM, Inc. has released its Q3 2026 financial results, providing insights into its performance and strategic direction within the agricultural services sector.

GlobalFoundries Reports Third Quarter 2026 Financial Results

GlobalFoundries announces third-quarter results, revealing $1.899 billion in revenue and a net loss of $270 million, emphasizing growth in AI and computing sectors.

Criteo reports Q3 2026 results with 9% media spend increase

Criteo S.A. announces Q3 2026 financial results, showing a 9% increase in media spend to $1.2 billion, highlighting growth in the advertising sector.

RYTHM, Inc. reports Q3 results, announces regulatory updates

RYTHM, Inc. announces Q3 results with a 4% revenue increase and key regulatory updates affecting the cannabis industry.

Pharmaceutical Resource Technology Reports Q3 Results

Pharmaceutical Resource Technology, Inc. releases its Q3 report, showcasing key financial metrics and operational updates for the construction industry.

Seres Therapeutics announces Q3 2026 results, SER-155 update

Seres Therapeutics reveals Q3 2026 financial results and plans for SER-155, targeting immune checkpoint inhibitor-related enterocolitis prevention.

MoonLake Immunotherapeutics Reports Q3 2026 Results, BLA Submitted

MoonLake Immunotherapeutics announces Q3 2026 financial results, including a BLA submission for sonelokimab to treat hidradenitis suppurativa.

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →